Compare Abeona Therapeutics Inc (ABEO) vs Kroger Co (KR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Kroger Co — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Kroger Co trades at $59.05 (market cap $35.86B). The key difference: Kroger Co is far larger — about 96.1× Abeona Therapeutics Inc's market cap, and Kroger Co pays a 2.46% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KR | |
|---|---|---|
Market Cap | $373.32M | $35.86B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $75.60 |
52-Week Low | $4.17 | $55.53 |
Enterprise Value | $228.22M | $55.96B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Kroger (KR) trades at $58.54, up 0.55% today, with a bearish technical signal but strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026. The company announced a $1.65 billion acquisition of Giant Eagle, expanding its Midwest footprint. Cash flow improved in 2025 with net cash flow of $2.08 billion, though net income margin remains thin at 0.71%.
Outlook is cautiously optimistic with a $67.29 price target, but risks include competitive pressures and rising debt. The stock offers growth through strategic acquisitions and dividend hikes, yet faces margin compression and integration challenges from recent deals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
